Gilead's Q3 results exceeded expectations, with EPS of $2.47 and revenue of $7.8 billion, driven by HIV franchise ...

Still riding the high of last year’s twice-yearly HIV PrEP approval of lenacapavir as Yeztugo, Gilead Sciences is approaching ...

The J.P. Morgan Healthcare Conference, as well as Fierce's own JPM Week, roll into Wednesday with plenty more events, ...

Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...

At a J.P. Morgan media event Tuesday, the Gilead C-suite seemed to be walking on air as they highlighted Yeztugo’s capture of ...

A Gilead Sciences executive who left the San Fransisco pharmaceutical giant last month after nearly four years, has been ...

Veteran biotech investors may recall the “Four Horsemen” of the megacap space, but in the years since, only one has truly stood the test of time. While Celgene was absorbed by Bristol Myers in early ...

Choose San Francisco Business Times as a preferred news source to see more of our reporting on Google. "I believe we rarely ...

Pharmas will need to provide their latest stance on the Most Favored Nation drug pricing plans, while biotech finally gets a ...

A Relative Strength Rating upgrade for Gilead Sciences shows improving technical performance. Will it continue?

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...